Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Karcinoza možganskih ovojnic in rak dojk : 11-letni rezultati zdravljenja z obsevanjem
Authors:ID Žnidarič, Tanja (Author)
ID Ratoša, Ivica (Author)
Files:.pdf PDF - Presentation file, download (283,45 KB)
MD5: A2E3D24693397ABA093EAF1FDDC5A69E
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Uvod: Karcinoza možganskih ovojnic (LMK) nastane z zasevanjem tumorskih celic na možganske ovojnice in pomeni slabo prognozo. Obsevanje je ena izmed možnosti zdravljenja za ublažitev nevroloških simptomov. Metode: V retrospektivno analizo smo vključili 423 bolnic z rakom dojke (RD) in možganskimi zasevki (MZ) ali LMK, ki so se v obdobju med 2005 in 2015 z obsevanjem glave zdravile na Onkološkem inštitutu Ljubljana. Podrobneje smo analizirali skupino bolnic z LMK, za katere smo tudi preverili uporabnost dveh prognostičnih lestvic preživetja, Breast Graded Prognostic Assessment (Breast-GPA) in Simple Survival Score for Brain Metastases (SS-BM). Rezultati: Z obsevanjem glave smo v opazovanem obdobju zdravili 70 bolnic z LMK. Srednji čas od diagnoze RD do pojava LMK je znašal 4,3 leta, vendar je bil ta čas najkrajši pri trojno negativnem in najdaljši pri luminal A podtipu RD. Srednje celokupno preživetje je za bolnice z MZ in LMK znašalo 7,5 (95-% interval zaupanja, IZ; 6,3%8,8) in 2,3 meseca (95-% IZ; 1,5%3,2) (p < 0,005) ter se je razlikovalo glede na molekularni podtip RD. Na daljše preživetje ni vplivala višja prejeta doza obsevanja (% 20 Gy vs. > 20 Gy). Z analizo smo potrdili prognostično vrednost lestvice Breast-GPA (p < 0,005) in SS-BM (p = 0,044). Zaključki: Pričakovano preživetje se je v naši skupini analiziranih bolnic z LMK razlikovalo glede na stanje zmogljivosti, molekularni podtip RD ter seštevek točk prognostične lestvice.
Keywords:rak dojke, karcinoza možganskih ovojnic, obsevanje, radioterapija
Publication status:Published
Publication version:Version of Record
Year of publishing:2019
Number of pages:str. 18-26
Numbering:Letn. 23, št. 1
PID:20.500.12556/DiRROS-9515 New window
UDC:615.82/.84
ISSN on article:1408-1741
COBISS.SI-ID:3257979 New window
Copyright:by Authors
Publication date in DiRROS:26.06.2019
Views:3920
Downloads:943
Metadata:XML DC-XML DC-RDF
:
ŽNIDARIČ, Tanja and RATOŠA, Ivica, 2019, Karcinoza možganskih ovojnic in rak dojk : 11-letni rezultati zdravljenja z obsevanjem. Onkologija [online]. 2019. Vol. 23, no. 1, p. 18–26. [Accessed 30 March 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=9515
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:26.06.2019

Secondary language

Language:English
Title:Leptomeningeal carcinomatosis and breast cancer : 11-year treatment outcomes with radiation therapy
Abstract:Introduction: Leptomeningeal carcinomatosis (LMC) develops with infiltration of leptomeninges by malignant cells and means poor prognosis. Radiotherapy presents one of the treatment options for neurological symptom relief. Methods: We retrospectively analyzed 423 patients with breast cancer (BC) and brain metastasis (BM) or LMC, who received radiotherapy of the brain between the years 2005 and 2015 at the Institute of Oncology Ljubljana. We analyzed patients with LMC in more detail and performed a validation of prognostic survival indexes, namely Breast Graded Prognostic Assessment (Breast-GPA) and Simple Survival Score for Brain Metastases (SS-BM). Results: Seventy patients with LMC were treated with whole-brain radiotherapy in the observed time. Median time from BC diagnosis to LMC appearance was 4.3 years and was shortest in triple-negative and longest in luminal A BC subtype. Median overall survival for patients with BM and LMC was 7.5 (95 % confidence interval, CI; 6.3%8.8) and 2.3 months (95 % CI; 1.5%3.2), respectively (p < 0,005), and it varied depending on the molecular BC subtype. Survival was not affected by a higher total dose of radiation received (% 20 Gy vs. > 20 Gy). Breast-GPA (p < 0,005) and SS-BM (p = 0,044) indexes predicted survival with statistical significance. Conclusions: Performance status, BC molecular subtype and prognostic indexes were all factors influencing expected survival in our group of analyzed LMC patients.
Keywords:breast cancer, leptomeningeal carcinomatosis, radiotherapy


Archive

niGradiv

Back